Compare AbbVie Inc (ABBV) vs S&P Global Inc (SPGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs S&P Global Inc — how do they compare? AbbVie Inc trades at $253.95 (market cap $449.91B), while S&P Global Inc trades at $433.26 (market cap $131.26B). The key difference: AbbVie Inc is far larger — about 3.4× S&P Global Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | SPGI | |
|---|---|---|
Market Cap | $449.91B | $131.26B |
Sector | Health | Financials |
52-Week High | $261.07 | $534.79 |
52-Week Low | $184.85 | $370.42 |
Enterprise Value | $513.38B | $143.23B |
Dividend Yield | 2.72% | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
S&P Global (SPGI) trades at $443.46, up 0.81% with strong bullish momentum. The stock shows robust fundamentals with 29.15% net margin and consistent earnings beats in three of the last four quarters. Recent completion of Mobility Global spinoff and AI-driven market intelligence initiatives position the company for growth. Technical indicators show bullish moving averages while RSI suggests potential overbought conditions near-term.
Outlook remains positive with 85.7% analyst buy ratings and $533.50 consensus target implying 20% upside. Key risks include interest rate sensitivity in credit rating segment and execution of AI transformation. The company's subscription-based revenue model and market data dominance provide stable cash flow foundation for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
